Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT)

NCT00215007 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2007-11-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of levofloxacin to prevent bacterial infections in the postneutropenic period in patients who have undergone allogeneic stem cell transplantation (SCT).

Conditions

  • Malignancy
  • Allogeneic Stem Cell Transplantation

Interventions

DRUG

Levofloxacin

Sponsors & Collaborators

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Igor Wolfgang Blau, Dr. · Charite, CBF, Berlin, Germany

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00215007 on ClinicalTrials.gov